Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group
by Shane Granger
The Therapeutic Goods Administration (TGA) has updated its latest safety report with no new deaths reported. Via the TGA. COVID-19 vaccine weekly safety report – 24-06-2021. Summary:
- The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
- Five additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the UK case definition, three were confirmed and two were deemed probable TTS. However, following reassessment of a previously reported case as being unlikely to be TTS, there is only a net increase of four cases. This brings the total number of cases of TTS to 64.
- We are also monitoring reports of suspected myocarditis and pericarditis following vaccination with Comirnaty and suspected Guillain-Barre Syndrome following vaccination with the AstraZeneca vaccine. No causal association with either vaccine has been established at this stage.
There have been approximately 4.2-million doses of AstraZeneca administered to 21 June (h/t Jack). On 17 June 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) recommended that Pfizer’s Comirnaty vaccine be preferred over the AstraZeneca vaccine for those aged 16–60 years old. To date there have been two TTS deaths linked to the AstraZeneca vaccine meaning you have an approx. 1/2.1-million chance of dying.